KIMS O&M units: Sangli and Guntur EBITDA positive in Q2FY27

In Q2FY27, KIMS Hospitals reported positive earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 2.47 crore at Sangli and Rs 2.66 crore at Guntur, while Kompally recorded an EBITDA loss of Rs 2.27 crore despite revenue of Rs 22.64 crore. Revenue and EBITDA are based on management accounts.

Which KIMS O&M hospitals were profitable in Q2FY27?

KIMS reported positive Q2FY27 EBITDA at Sangli and Guntur, while Kompally remained loss-making. Sangli generated revenue of Rs 28.48 crore and EBITDA of Rs 2.47 crore, compared with revenue of Rs 35.14 crore and EBITDA of Rs 2.66 crore at Guntur. Kompally generated Rs 22.64 crore of revenue and reported negative EBITDA of Rs 2.27 crore.

Guntur had the highest revenue and EBITDA among the three operations-and-management (O&M) hospitals in Q2FY27. Sangli's EBITDA of Rs 2.47 crore was Rs 19 lakh below Guntur's Rs 2.66 crore, although Sangli reported Rs 6.66 crore less revenue. KIMS states that the revenue and EBITDA figures for these units are management-account figures.

Sangli was EBITDA positive in all three reported periods. Its revenue increased from Rs 24.76 crore in Q2FY26 to Rs 27.74 crore in Q1FY27 and Rs 28.48 crore in Q2FY27. EBITDA rose from Rs 1.42 crore in Q2FY26 to Rs 2.26 crore in Q1FY27 and Rs 2.47 crore in Q2FY27.

How did KIMS Guntur move from a loss to positive EBITDA?

Guntur moved from an EBITDA loss of Rs 3.09 crore in Q2FY26 to EBITDA of Rs 1.87 crore in Q1FY27 and Rs 2.66 crore in Q2FY27. Revenue increased over the same periods from Rs 23.08 crore to Rs 31.79 crore and then Rs 35.14 crore.

The change is visible both year on year and sequentially. From Q2FY26 to Q2FY27, Guntur's revenue increased by Rs 12.06 crore and EBITDA improved by Rs 5.75 crore, moving from a loss to a positive result. From Q1FY27 to Q2FY27, revenue rose by Rs 3.35 crore and EBITDA increased by Rs 79 lakh.

KIMS reported 1,316 surgeries across specialties at Guntur, alongside 13 high-risk complex procedures and more than seven liver and kidney transplants. The high-risk procedures covered cardiology, pulmonology, paediatric cardiothoracic and vascular surgery, neurosurgery and plastic surgery, but the presentation does not allocate revenue or EBITDA to individual services.

Guntur's National Accreditation Board for Hospitals & Healthcare Providers (NABH) status was listed as in pipeline. The presentation therefore does not report completed NABH accreditation for the unit, nor does it give an expected completion date.

Why is KIMS Kompally still reporting an EBITDA loss?

Kompally remained EBITDA negative in Q2FY27, and KIMS did not disclose a specific reason for the loss. The unit reported revenue of Rs 22.64 crore and an EBITDA loss of Rs 2.27 crore, compared with revenue of Rs 12.14 crore and an EBITDA loss of Rs 9.21 crore in Q1FY27.

Revenue expanded by Rs 10.50 crore between Q1FY27 and Q2FY27, while the EBITDA deficit reduced by Rs 6.94 crore. These are Kompally's first two reported periods in the presentation, so KIMS did not provide a Q2FY26 comparison. Its Q2FY27 revenue remained below Sangli's Rs 28.48 crore and Guntur's Rs 35.14 crore.

KIMS reported more than 900 surgeries across all specialties at Kompally and said it launched oncology services. The presentation does not quantify the revenue or EBITDA contribution from oncology, surgeries or any other clinical service, and it does not state when the hospital is expected to reach positive EBITDA.

What operating milestones did KIMS disclose at its O&M hospitals?

KIMS disclosed separate clinical and patient-access developments at each O&M hospital in Q2FY27. Sangli empanelled key insurance partners and performed a cadaveric kidney transplant, while Guntur reported 1,316 surgeries and more than seven liver and kidney transplants. Kompally performed more than 900 surgeries and added oncology services.

Sangli's revenue increased by Rs 3.72 crore from Q2FY26 to Q2FY27, while its EBITDA rose by Rs 1.05 crore over that period. Guntur recorded a larger revenue increase of Rs 12.06 crore and EBITDA improvement of Rs 5.75 crore, starting from a Q2FY26 EBITDA loss of Rs 3.09 crore.

All three O&M hospitals were listed as having NABH accreditation in pipeline. KIMS did not provide a target completion date for Sangli, Guntur or Kompally, and did not disclose unit-level bed capacity, occupancy, average revenue per occupied bed, payor mix or capital spending.

Conclusion

KIMS's Q2FY27 O&M figures show two hospitals reporting positive EBITDA and one reporting a smaller loss alongside higher revenue. Sangli delivered EBITDA of Rs 2.47 crore on revenue of Rs 28.48 crore, while Guntur delivered Rs 2.66 crore on revenue of Rs 35.14 crore after reporting a Rs 3.09 crore loss in Q2FY26. Kompally's loss of Rs 2.27 crore was lower than its Rs 9.21 crore loss in Q1FY27.

The next disclosures to watch are Kompally's progress from its Q2FY27 EBITDA loss, the reported financial effect of its oncology launch and surgery volumes, and changes in NABH status at all three O&M hospitals. KIMS lists accreditation as in pipeline for Sangli, Guntur and Kompally but gives no timetable or unit-level profitability target.